Silvia de Sanjosé, MD, PhD
IPVS President

Dear Member,

**IPVS 2016**
This is the second IPVS Newsletter since our meeting in Lisbon. Since then we have been working hard to prepare the next IPVS conference in Cape Town, South Africa. You can already see on the web the preliminary programme. As soon as inscription fees are available we encourage you to register as 'Earlybirds' to guarantee a better rate! There is about a great deal of buzz surrounding the Cape Town conference and we are thoroughly convinced that the region will benefit from all of your scientific efforts.

**IPVS 2018**
It is with a great pleasure we announce Sidney as the site selected for IPVS 2018. We have already started to work with Prof. Canfell and colleagues to help with the logistics and organisation. We hope that some of the activities held during the Cape Town meeting will be linked with those of Sidney to provide a deep sense of continuity particularly for the workshops. We will keep you updated on our progress.

**Membership Update**
I am also glad to inform that the IPVS now has 530 members! So, Joel’s goal has been reached!
The IPVS Board members are planning a meeting during the Eurogin Conference in Salzburg. During the meeting, we will work on the IPVS strategic plan and different working groups will be created. A call for participation will be open on due time. It is our hope that these working groups will be involve many members so that you can actively participate in the future planning of the Society.

We congratulate our board member Prof. Xavier Bosch who has been nominated Honoris Causa by the University of Barcelona for his contribution in the fields of epidemiology, HPV and cancer.

**International Women’s Day 2016**

With the issue of our second IPVS Newsletter, 8 March 2016 also marks International Women’s Day. As the Society leading the fight against HPV and its impact on health, women are an IPVS priority as globally they have the largest burden of HPV infection. Therefore, it is important that women get to know what the scientific community and the IPVS knows about HPV disease and how to prevent it. I encourage all of our members to make every day an International Women’s Day and to take any opportunity to be advocates for women’s health.

Silvia de Sanjosé

---

**HPV 2018**

After a thorough evaluation of the different proposals for the next IPV conference to take place in 2018, the IPVS Board vote chose Sydney as the destination for HPV 2018 Conference!

Congratulations to Sydney!

---

**Vaincre la Papillomatose Respiratoire Récursive**

(To win against recurrent respiratory Papillomatosis)

In December 2014 was founded a local group in France gathering about 30 patients and family members to date. As the Recurrent Respiratory Papillomatosis Foundation (RRPF), our
association is aimed at helping patients with administrative problems, gathering information about the disease, talking about alternative treatments, talking to the ents specialists.

We would like to meet other associations in other countries, in order to share information about treatments, difficulties of patients, and new researches and treatment tests.

Besides anyone interested in joining is welcome, along with the RRPF. Please contact Colette Petit Le Bâcle: colette.lebacle@vaincreprr.fr

www.vaincreprr.fr
www.RRPF.org

HPV Vaccine Lessons Learnt
Resources now Available

The increasing burden of cervical cancer means it is a critical time to expand evidence-based delivery of HPV vaccines. In the past ten years, dozens of countries have included HPV vaccine into their national immunisation schedule and many low- and middle-income countries have gained experience in HPV vaccine delivery through demonstration projects and national programmes.

The London School of Hygiene & Tropical Medicine and PATH recently completed the first comprehensive review of HPV vaccine delivery experiences across 37 low- and middle-income countries. These activities represent eight

University of Barcelona invest
doctor honors causa the oncologist and epidemiologist F. Xavier Bosch

The oncologist and epidemiologist F. Xavier Bosch has been awarded an honorary doctorate (Honoris Causa) by the University of Barcelona on February 11th, 2016.

At the ceremony, which was held in the Paranimf, have acted as guarantors Francesc Cardellach, dean of the Faculty of Medicine, UB, and Victor Raul Moreno, professor of the Department of Clinical Sciences. Read more

- Call for nominations -
Maurice Hilleman Award

The International Papillomavirus Society and Eurogin are pleased to solicit your nominations for the recipient of the 2016 Maurice Hilleman Award. Sponsored by Merck and Co, the Maurice Hilleman award honors the memory of Maurice Hilleman, PhD, one of the most productive vaccinologists in history.

The 2016 Maurice Hilleman Award will be given to a scientist in recognition of his or her outstanding contributions to the development and/or implementation of HPV vaccines. Read more here

Since its foundation, the mission of IPVS has been to facilitate research on human and animal papillomaviruses
n national programmes and 55 demonstration projects – some of which implemented multiple delivery strategies – resulting in 72 distinct vaccine delivery experiences.

These experiences have helped countries learn valuable lessons about effective methods for garnering parental acceptance and reaching young adolescent girls with the vaccine, at relatively low delivery costs. The lessons learnt from these countries can provide critical information for policy makers and programme planners on how best to prepare, deliver, and sustain HPV vaccines.

A package of materials synthesizing findings from this review is now available at [www.rho.org/HPVlessons](http://www.rho.org/HPVlessons).

For a quick preview, watch our brief video at [www.rho.org/HPVlessons-video](http://www.rho.org/HPVlessons-video).

Highlights include key findings and lessons from HPV vaccination experience across five themes: preparation, communications, delivery, achievements, and sustainability. Also addressed are the value of demonstration projects and potential HPV vaccination pitfalls.

United Nations message on World Cancer Day

As part of the Celebrations for the World Cancer Day on February 4th, the United Nations Secretary-General Dr Ban Ki-moon sent a message about the need for additional work for reducing the suffering associated to cancer (see below). The message specifically highlighted the cervical cancer burden, and that most of the cases and deaths due to this cancer are in developing countries. [Read more](http://www.un.org/en/events/worldcancerday/)
immunization schedule:

- The order of vaccines has been changed to group vaccines by recommended age of administration. The order of footnotes also has been changed.
- A purple bar was added for Haemophilus influenzae type b vaccine for children ages 5 through 18 years to denote the recommendation to vaccinate certain unimmunized high-risk children in this age group.
- A purple bar has been added for HPV vaccine for children starting at 9 years of age with a history of sexual abuse.
- A new row has been added for meningococcal B vaccine. A purple bar indicates the recommendation to vaccinate certain high-risk people ages 10 years and older. A blue bar indicates the recommendation for permissive administration to non-high risk groups subject to individual decision-making for those 16 through 18 years.
- In the catch-up schedule, Tdap/Td was added to the list of possible previous vaccines in the Tdap line for children ages 7 years and older, dose 2 to dose 3 column.

Changes to the 2016 footnotes include:

- The hepatitis B vaccine footnote was revised to present the timing for post vaccination serologic testing for infants born to hepatitis B surface antigen positive mothers.
- The DTaP footnote was clarified to present recommendations following an inadvertent early fourth dose of DTaP vaccine.
- The inactivated polio vaccine footnote was updated to provide guidance for vaccination of people who received only oral polio vaccine and received all doses before 4 years of age.
- The footnotes for the meningococcal vaccines were updated to include recommendations for administration of the meningococcal B vaccine.
- The HPV footnote has been updated to reflect the 9-valent nomenclature (9vHPV). Guidance has been added for vaccination beginning at 9 years of age for children with a history of sexual abuse, recognizing their increased risk of HPV infection.

More information on [http://www.cdc.gov/vaccines/schedules/index.html](http://www.cdc.gov/vaccines/schedules/index.html)
HPV 2017 website is now live! More information about abstract submission and registration is coming up soon!

Copyright © 2016 International Papillomavirus Society, All rights reserved.
You are receiving this email because you attended HPV 2015 conference

Our mailing address is:
International Papillomavirus Society
7 rue François Versonnex
Geneva 1207
Switzerland

Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.